Canine Lymphoma: Treatment Decisions, Quality of Life, and End-of-Life Care

Lymphoma is one of the most common cancers in dogs, and the decisions owners face about treatment, quality of life, and end-of-life care are among the most difficult in veterinary medicine. Understanding the options helps owners make welfare-centred choices.

Key Facts

Canine lymphoma (lymphosarcoma) accounts for approximately 7-24% of all canine cancers and is among the most common cancers in dogs, arising from lymphocytes in lymph nodes, spleen, liver, bone marrow, or other organs
The most common form is multicentric lymphoma — generalised enlargement of peripheral lymph nodes — which is often first noticed by owners or veterinarians as firm, painless swellings
Without treatment, most dogs with multicentric high-grade lymphoma survive only 4-6 weeks from diagnosis; with chemotherapy, median survival extends to 12-14 months, with 20-25% surviving 2 years
The CHOP chemotherapy protocol (cyclophosphamide, doxorubicin, vincristine, prednisone) is the gold standard treatment and is generally well-tolerated by dogs, with most maintaining good quality of life during treatment
Unlike human chemotherapy, veterinary oncology protocols prioritise quality of life over maximum tumour response — lower doses are used and aggressive side effects are not considered acceptable
Prednisone (steroid) alone extends survival by 1-2 months compared to no treatment and may maintain reasonable quality of life for dogs whose owners cannot pursue full chemotherapy
Relapse is nearly universal; rescue protocols can achieve second remissions but these are typically shorter than first remissions
Certain breeds including Golden Retrievers, Boxers, Saint Bernards, Basset Hounds, and Rottweilers have higher incidence, suggesting genetic predisposition

Welfare Considerations

Canine lymphoma forces owners to confront profound welfare questions about the balance between extending life and maintaining quality of life. The excellent initial chemotherapy response rates are genuinely encouraging, but the near-universal relapse and the reality that treatment extends life rather than cures means owners must maintain an ongoing welfare assessment throughout the treatment period. Key welfare indicators during chemotherapy include maintaining appetite, interest in activities the dog previously enjoyed, normal mobility, and absence of distressing side effects. A dog that is nauseated, extremely fatigued, or in pain during treatment is experiencing worse welfare than one whose cancer progresses untreated — quality of life must remain the primary metric. Veterinary oncology's emphasis on quality-of-life-preserving protocols over maximal tumour suppression is an important ethical commitment that distinguishes animal from human oncology. End-of-life decisions are among the most difficult, and owners benefit from honest, compassionate communication from their veterinary team about prognosis, what deterioration looks like, and how to recognise when the right time for euthanasia has arrived.

What You Can Do

Seek referral to a veterinary oncologist if your dog is diagnosed with lymphoma — specialist guidance on treatment protocols, monitoring, and side effect management significantly improves outcomes
Have a frank discussion with your vet or oncologist about realistic prognosis and quality-of-life expectations before committing to treatment — informed consent requires understanding both benefits and burdens
Monitor your dog's quality of life throughout treatment using validated quality-of-life scales; many veterinary oncology centres provide these tools to guide treatment decisions
Do not feel obligated to pursue aggressive treatment if your circumstances do not permit it — prednisone alone or palliative care focused on comfort and quality of life are ethical choices
Plan end-of-life care proactively: discuss euthanasia with your vet before a crisis point, understand what signs indicate the right time, and consider home euthanasia options that reduce distress
Support canine cancer research through donations to organisations funding clinical trials and genetic studies that may eventually improve lymphoma prevention, treatment, and cure rates